Home > Compound List > Compound details
63590-64-7 molecular structure
click picture or here to close

6,7-dimethoxy-2-[4-(oxolane-2-carbonyl)piperazin-1-yl]quinazolin-4-amine

ChemBase ID: 1033
Molecular Formular: C19H25N5O4
Molecular Mass: 387.4329
Monoisotopic Mass: 387.19065431
SMILES and InChIs

SMILES:
O1C(CCC1)C(=O)N1CCN(CC1)c1nc2c(c(n1)N)cc(OC)c(OC)c2
Canonical SMILES:
COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)C1CCCO1
InChI:
InChI=1S/C19H25N5O4/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14/h10-11,14H,3-9H2,1-2H3,(H2,20,21,22)
InChIKey:
VCKUSRYTPJJLNI-UHFFFAOYSA-N

Cite this record

CBID:1033 http://www.chembase.cn/molecule-1033.html

Collapse All Expand All

NAMES AND DATABASE IDS

NAMES AND DATABASE IDS

Names Database IDs
IUPAC name
6,7-dimethoxy-2-[4-(oxolane-2-carbonyl)piperazin-1-yl]quinazolin-4-amine
IUPAC Traditional name
6,7-dimethoxy-2-[4-(oxolane-2-carbonyl)piperazin-1-yl]quinazolin-4-amine
terazosin
Brand Name
Blavin
Flumarc
Fosfomic
Heitrin
Hytracin
Hytrin
Hytrinex
Itrin
Urodie
Vasomet
Vicard
Synonyms
Terazosin HCl
Terazosin hydrochloride
Terazosina [INN-Spanish]
Terazosine
Terazosine [INN-French]
Terazosinum [INN-Latin]
Trazosin HCl
Abbott 45975
Terazosin
6,7-dimethoxy-2-[4-(oxolane-2-carbonyl)piperazin-1-yl]quinazolin-4-amine
CAS Number
63590-64-7
MDL Number
MFCD00072144
PubChem SID
46509129
160964496
PubChem CID
5401

DATA SOURCES

DATA SOURCES

All Sources Commercial Sources Non-commercial Sources
Data Source Data ID Price
Enamine
EN300-119614 external link Add to cart Please log in.

CALCULATED PROPERTIES

CALCULATED PROPERTIES

JChem ALOGPS 2.1
Acid pKa 19.929197  H Acceptors
H Donor LogD (pH = 5.5) -0.32373834 
LogD (pH = 7.4) 0.95433736  Log P 1.1797276 
Molar Refractivity 105.1764 cm3 Polarizability 40.394585 Å3
Polar Surface Area 103.04 Å2 Rotatable Bonds
Lipinski's Rule of Five true 
Log P 1.12  LOG S -2.41 
Solubility (Water) 1.50e+00 g/l 

PROPERTIES

PROPERTIES

Physical Property Product Information Bioassay(PubChem)
Solubility
29.7mg/mL expand Show data source
Hydrophobicity(logP)
1 expand Show data source
2.182 expand Show data source
Purity
95% expand Show data source

DETAILS

DETAILS

DrugBank DrugBank
DrugBank - DB01162 external link
Item Information
Drug Groups approved
Description Terazosin is a selective alpha1-antagonist used for treatment of symptoms of benign prostatic hyperplasia (BPH). It also acts to lower blood pressure, so it is a drug of choice for men with hypertension and prostate enlargement. It works by blocking the action of adrenaline on smooth muscle of the bladder and the blood vessel walls.
Indication For the treatment of symptomatic BPH and mild to moderate hypertension.
Pharmacology Terazosin, classified as a quinazoline, is similar to doxazosin and prazosin. As an α-adrenergic blocking agent, terazosin is used to treat hypertension and BPH. Terazosin produces vasodilation and reduces peripheral resistance but in general has only a slight effect on cardiac output. The antihypertensive effect with chronic dosing is not usually accompanied by reflex tachycardia.
Toxicity LD50=259.3mg/kg (IV in mice)
Affected Organisms
Humans and other mammals
Biotransformation Hepatic. One of the four metabolites identified (piperazine derivative of terazosin) has antihypertensive activity.
Absorption Essentially completely absorbed in man (90% bioavailability).
Half Life 12 hours
Protein Binding 90-94%
Elimination Approximately 10% of an orally administered dose is excreted as parent drug in the urine and approximately 20% is excreted in the feces.
References
Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, Black HR, Hamilton BP, Holland J, Nwachuku C, Papademetriou V, Probstfield J, Wright JT Jr, Alderman MH, Weiss RJ, Piller L, Bettencourt J, Walsh SM: Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich). 2002 Nov-Dec;4(6):393-404. [Pubmed]
External Links
Wikipedia
RxList
Drugs.com

REFERENCES

REFERENCES

From Suppliers Google Scholar IconGoogle Scholar PubMed iconPubMed Google Books IconGoogle Books
  • • Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, Black HR, Hamilton BP, Holland J, Nwachuku C, Papademetriou V, Probstfield J, Wright JT Jr, Alderman MH, Weiss RJ, Piller L, Bettencourt J, Walsh SM: Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich). 2002 Nov-Dec;4(6):393-404. Pubmed
  • Searching...Please wait...

PATENTS

PATENTS

PubChem iconPubChem Patent Google Patent Search IconGoogle Patent

INTERNET

INTERNET

Baidu iconBaidu google iconGoogle